Report

QuickView: Aiming for dry AMD

Acucela recently published overall encouraging Phase IIa data for its lead dry AMD compound, emixustat, which is being developed in collaboration with Otsuka. The study proved emixustat modulates the visual cycle and provided proof of concept to continue development. A Phase IIb/III study with emixustat has fully enrolled and data are expected in Q316. Otsuka is co-funding the studies and will co-promote in North America (35-50% profit share to Acucela) or fully commercialise (19-23% royalties).
Underlying
Provider
Edison Investment Research
Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

.

Other Reports on these Companies
Other Reports from Edison Investment Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch